Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 11.76B | 11.01B | 10.94B | 10.93B | 9.56B |
Gross Profit | 6.83B | 7.92B | 7.68B | 7.82B | 6.91B |
EBITDA | 5.21B | 7.20B | 7.08B | 7.26B | -728.00M |
Net Income | 1.61B | 2.81B | 2.72B | 2.59B | -1.54B |
Balance Sheet | |||||
Total Assets | 234.97B | 231.45B | 226.54B | 238.03B | 224.75B |
Cash, Cash Equivalents and Short-Term Investments | 10.82B | 6.34B | 5.79B | 9.14B | 6.79B |
Total Debt | 58.06B | 50.97B | 46.25B | 46.22B | 39.10B |
Total Liabilities | 82.28B | 76.54B | 71.33B | 73.54B | 65.41B |
Stockholders Equity | 95.78B | 94.36B | 92.82B | 95.84B | 92.11B |
Cash Flow | |||||
Free Cash Flow | 5.04B | 3.91B | 378.00M | -1.14B | -546.00M |
Operating Cash Flow | 5.21B | 4.02B | 3.10B | 1.74B | 2.58B |
Investing Cash Flow | -3.07B | -2.85B | -4.18B | -1.95B | -2.57B |
Financing Cash Flow | 2.38B | -566.00M | -1.93B | 3.63B | 3.61B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | HK$18.57B | 11.51 | 1.69% | 9.53% | 8.13% | -42.62% | |
69 Neutral | $128.54B | 20.41 | 1.94% | 9.79% | -7.64% | -32.01% | |
63 Neutral | $11.02B | ― | -3.12% | 6.78% | 2.20% | -327.14% | |
54 Neutral | $1.19B | 3.66 | 0.13% | 6.36% | -2.13% | -128.06% | |
50 Neutral | $14.09B | ― | -10.34% | 8.93% | -56.64% | -3398.20% | |
47 Neutral | $1.93B | ― | -2.65% | ― | 11.74% | -21.82% | |
46 Neutral | HK$5.27B | ― | -0.98% | 1.95% | 48.92% | -176.75% |
Hang Lung Group Limited has announced that its board of directors will convene on July 30, 2025, to approve the interim results for the first half of the year and to consider the payment of an interim dividend. This meeting is significant as it will provide insights into the company’s financial performance and potential returns for shareholders, reflecting its strategic positioning in the real estate market.
Hang Lung Group Limited announced the successful approval of all proposed resolutions at its annual general meeting held on April 30, 2025. Key resolutions included the approval of audited financial statements, declaration of a final dividend, re-election of directors, re-appointment of KPMG as auditor, and granting of mandates to the board for share buybacks and issuance. These approvals are expected to strengthen the company’s governance and operational capabilities, potentially enhancing its market position and stakeholder confidence.